In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Nabriva (NBRV – Research Report). The company’s shares closed last Monday at $0.59, close to its 52-week low of $0.56.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.1% and a 38.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Nabriva.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.49 and a one-year low of $0.56. Currently, Nabriva has an average volume of 826.4K.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBRV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Read More on NBRV:
